[99mTc]Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of metastatic brain tumors and high-grade gliomas

Vallejo-Armenta, Paola; Soto-Andonaegui, Juan; Villanueva-Pérez, R.M.; González‐Díaz, Jorge Iván; Contreras-Contreras, Keren; Bautista-Wong, Claudia G.; Sandoval-Bonilla, Bayron A.; Nettel-Rueda, Bárbara; Santos-Cuevas, Clara; Ferro-Flores, Guillermina

doi:10.1016/j.nucmedbio.2021.02.003

Cited by 11 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for manifestations, MTB is also characterized by intracranial neurological symptoms rather than the primary tumor. In some cases of MTB, even the primary tumor cannot be found, which can only be diagnosed through pathological examination after surgery ( Vallejo-Armenta et al, 2021 ). Such MTB can easily be misdiagnosed as GL, which seriously affects the timely and correct treatment of patients.…”

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation of contrast-enhanced magnetic resonance imaging in differentiating glioma from metastatic tumor of the brain and exploration of its association with patients’ neurological function

Shi

Jiang²,

Xie³

et al. 2022

Front. Behav. Neurosci.

View full text Add to dashboard Cite

ObjectiveTo determine the efficacy of contrast-enhanced MRI in differentiating glioma (GL) from the metastatic tumor of the brain (MTB) and its association with patients’ neurological function.MethodsA retrospective analysis was conducted on 49 cases of pathologically confirmed GL and 42 cases of MTB admitted between April 2019 and January 2022. All patients were examined by a set of MRI sequences that included T1WI, T2WI, FLAIR, and DWI. The values of fractional anisotropy (FA), apparent diffusion coefficient (ADC), and operation coefficient (Ktrans) were calculated by taking the tumor parenchyma area, cystic area, and peritumor edema area as the regions of interest (ROIs). And according to the Mini-mental state examination (MMSE) results, the contrast-enhanced MRI with patients’ neurological dysfunction was observed.ResultsThe clinical symptoms and MRI findings of MTB and GL were basically the same, mainly showing neurological symptoms. The tumor parenchyma area and cystic area were mainly located in the tumor periphery and tumor central area, respectively, while the peritumor edema area was widely distributed, showing an irregular patchy edema zone. Contrast-enhanced scans suggested an obvious enhancement in the tumor parenchymal area, presenting with nodular and annular enhancement, but no enhancement in the tumor cystic and peritumor edema areas. There was no difference between GL and MTB in FA values of tumor cystic area and peritumor edema area (P > 0.05), but the FA value of the parenchyma area of GL was higher (P < 0.05). Besides, GL and MTB showed no difference in ADC and Ktrans values (P > 0.05), while the former presented lower ADC values and higher Ktrans values of the peritumor edema area than the latter (P < 0.05). In patients with GL and MTB, the FA and Ktrans values of all ROIs in those with neurological dysfunction were higher compared with those without neurological dysfunction, while the ADC values were lower (P < 0.05).ConclusionContrast-enhanced MRI of peritumor edema area can effectively distinguish GL from MTB, and improve the accuracy of early clinical screening, thus providing more reliable life security for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation of contrast-enhanced magnetic resonance imaging in differentiating glioma from metastatic tumor of the brain and exploration of its association with patients’ neurological function

Shi

Jiang²,

Xie³

et al. 2022

Front. Behav. Neurosci.

View full text Add to dashboard Cite

show abstract

“…The previous few years have seen an immense uptick in PSMA in glioma investigation with 42 publications on the topic from 2020 to date (July 2023). 5,[16][17][18][19][20][21][22][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]49,56,[60][61][62][63][64][65][66][67][68][69][70][71][72][73][74] These publications mainly focus on 3 fields of study: histopathology of PSMA in gliomas, use of PSMA imaging techniques in glioma diagnosis, and use of PSMA-targeted therapies in the treatment of gliomas.…”

Section: Glioblastomamentioning

confidence: 99%

Prostate-Specific Membrane Antigen Use in Glioma Management

McBriar,

Shafiian,

Scharf

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

Background Prostate-specific membrane antigen (PSMA) is a membrane-bound metallopeptidase highly expressed in the neovasculature of many solid tumors including gliomas. It is a particularly enticing therapeutic target due to its ability to internalize, thereby delivering radioligands or pharmaceuticals to the intracellular compartment. Targeting the neovasculature of gliomas using PSMA for diagnosis and management has been a recent area of increased study and promise. The purpose of this review is to synthesize the current state and future directions of PSMA use in the histopathologic study, imaging, and treatment of gliomas. Methods PubMed and Scopus databases were used to conduct a literature review on PSMA use in gliomas in June 2023. Terms searched included “PSMA,” “Prostate-Specific Membrane Antigen” OR “PSMA” OR “PSMA PET” AND “glioma” OR “high grade glioma” OR “glioblastoma” OR “GBM.” Results Ninety-four publications were screened for relevance with 61 studies, case reports, and reviews being read to provide comprehensive context for the historical, contemporary, and prospective use of PSMA in glioma management. Conclusions PSMA PET imaging is currently a promising and accurate radiographic tool for the diagnosis and management of gliomas. PSMA histopathology likely represents a viable tool for helping predict glioma behavior. More studies are needed to investigate the role of PSMA-targeted therapeutics in glioma management, but preliminary reports have indicated its potential usefulness in treatment.

show abstract

“…PSMA expression was significantly higher in HGG than in LGG. Vallejo-Armenta et al [31] presented a study with [ 99m Tc]Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of HGG and brain metastases. They confirmed accumulation in HGG and metastases but not in LGG and benign lesions.…”

Section: Glioma Suspicions and Differentiationmentioning

confidence: 99%

Prostate-specific membrane antigen expression in intracranial lesions — a review of the primary, metastatic, and nonneoplastic lesions

Pełka,

Bodys-Pełka,

Kunikowska

2023

Nucl. Med. Rev.

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a membrane protein originally discovered in prostate cancer cells. It is widely used at all stages of prostate cancer diagnosis. Several studies have highlighted its possible wide application in other cancers.This review discusses the potential use of positron emission tomography with labelled PSMA for the diagnosis or differentiation of intracranial lesions. Given the numerous reports on the usefulness of PSMA in the diagnosis of brain tumours of glial origin, the focus is on lesions of a different aetiology.

show abstract

[99mTc]Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of metastatic brain tumors and high-grade gliomas

Cited by 11 publications

References 19 publications

Efficacy evaluation of contrast-enhanced magnetic resonance imaging in differentiating glioma from metastatic tumor of the brain and exploration of its association with patients’ neurological function

Efficacy evaluation of contrast-enhanced magnetic resonance imaging in differentiating glioma from metastatic tumor of the brain and exploration of its association with patients’ neurological function

Prostate-Specific Membrane Antigen Use in Glioma Management

Prostate-specific membrane antigen expression in intracranial lesions — a review of the primary, metastatic, and nonneoplastic lesions

Contact Info

Product

Resources

About